Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry

Rheumatology (United Kingdom)

Volumn 55, Issue 2, 2015, Pages 286-290

  Yoshida, Kazuki ^a,b   Kishimoto, Mitsumasa ^c   Radner, Helga ^b,d   Matsui, Kazuo ^e   Okada, Masato ^c   Saeki, Yukihiko ^f   Solomon, Daniel H ^b   Tohma, Shigeto ^g  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e KAMEDA MEDICAL CENTER   (Japan)

^f MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^g SAGAMIHARA NATIONAL HOSPITAL   (Japan)

Author keywords

Antirheumatic agents; Biologic antirheumatic agents; Discontinuation; Remission; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; DISEASE CONTROL; DISEASE DURATION; DISEASE REGISTRY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE COURSE; JAPAN; REGISTER; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; REGISTRIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84961882177     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev329     Document Type: Article

References (20)

1. Tanaka Y, Hirata S. Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis. Drugs 2014;74:2129-39.
2. Van Herwaarden N, den Broeder AA, Jacobs W et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 2014;9:CD010455.
3. Yoshida K, Sung Y-K, Kavanaugh A et al. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis 2014;73:595-9.
4. Navarro-Millán I, Sattui SE, Curtis JR. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clin Ther 2013;35:1850-61.e1.
5. Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol 2006;16:75-6.
6. Varadhan R, Weiss CO, Segal JB et al. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 2010;48(6 Suppl):S96-105.
7. Smolen JS, Emery P, Fleischmann R et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383:321-32.
8. Van den Broek M, Klarenbeek NB, Dirven L et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011;70:1389-94.
9. Harigai M, Takeuchi T, Tanaka Y et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol 2012;22:814-22.
10. Smolen JS, Emery P, Ferraccioli G et al. Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab pegol treatment: week 52 results from the CERTAIN study [abstract]. Ann Rheum Dis 2012;71(Suppl3):361.
11. Van Vollenhoven R, Østergaard M, Leirisalo-Repo M et al. In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-armed, double-blind clinical trial [abstract]. Arthritis Rheum 2012;64(Suppl 10):4171.
12. Van der Maas A, Kievit W, van den Bemt BJF et al. Downtitration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012;71:1849-54.
13. Brocq O, Millasseau E, Albert C et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350-5.
14. Kavanaugh A, Lee SJ, Curtis JR et al. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Ann Rheum Dis 2015;74:1150-5.
15. Tanaka Y, Hirata S, Kubo S et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74:389-95.
16. Kurasawa T, Nagasawa H, Kishimoto M et al. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial. Mod Rheumatol 2014;24:561-6.
17. Emery P, Hammoudeh M, FitzGerald O et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 2014;371:1781-92.
18. Tanaka Y, Takeuchi T, Mimori T et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69: 1286-91.
19. Lillegraven S, Prince FHM, Shadick NA et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 2012;71:681-6.
20. Smolen JS, Nash P, Durez P et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.